Information Provided By:
Fly News Breaks for July 27, 2016
BMRN
Jul 27, 2016 | 16:05 EDT
Evercore ISI analyst Mark Schoenebaum says BioMarin's update data from its hemophilia A gene therapy program presented today shows continued durable FVIII expression. Further, while liver enzyme elevations appear to be more common than not at the high dose, they appear to be manageable with steroids and do not impact efficacy, he contended. Nonetheless, Schoenebaum notes that is still early and the longer follow up on these patients the better. Evercore ISI has a Buy rating and $99 price target on the shares.
News For BMRN From the Last 2 Days
There are no results for your query BMRN